A new era in migraine treatment begins now

Mentari Therapeutics is on a mission to bring freedom from migraine to as many people as possible. The company is developing a potentially best-in-class portfolio of targeted biologics for migraines, one of the most widespread and undertreated neurological conditions, affecting more than 1 billion people globally.

The arrival of anti-CGRP therapies marked a turning point in migraine care, but a significant unmet need remains, with a majority who suffer unable to achieve adequate relief. Mentari’s two lead programs target PACAP, a newly validated, distinct pathway in migraine biology. MT-001 is a potentially best-in-class anti-PACAP antibody, and MT-002 is a bispecific antibody designed to block both CGRP and PACAP, with the potential to provide superior efficacy compared to either monotherapy alone.

Both are being developed to deliver meaningfully better outcomes for those who have inadequate relief from migraines.